COPD

COPD patients have a significantly increased risk of developing nonamnestic mild cognitive impairment, according to the results of a study carried out by researchers at the Mayo Clinic.

The FDA has approved Anoro Ellipta (GlaxoSmithKline and Theravance, Inc) for maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease.

Although many COPD patients avoid exercise due to their breath-robbing condition, a new study finds that those who reported the most exercise and did not reduce their exercise level over time had the fewest hospitalizations for exacerbations.

Our round-up of the latest Rx products.

A 50-year-old male with a history of benign prostatic hyperplasia, chronic obstructive pulmonary disease, and type 2 diabetes mellitus is admitted for a laparoscopic colectomy. The patient's surgeon requests a pharmacy consultation to develop a multimodal, opioid-sparing pain control regimen.

COPD patients treated with N-acetylcysteine had significantly fewer exacerbations than patients treated with placebo, but more data is needed before the compound can be made an integral component of treatment guidelines.

OTC case studies involving oral ulcerations, fungal infections, immunizations for a patient receiving corticosteroid therapy, and dry mouth.

A study evaluating the safety of benzodiazepines and opioids in chronic obstructive pulmonary disease patients finds that low-dose opioids may be safe for treating breathlessness in patients with severe cases.

Medication use improved in COPD and asthma patients whose community pharmacists intervened to address a range of potential problems.

A study of COPD patients found that, on average, their exercise capacity declined over time and that just 5% enrolled in pulmonary rehabilitation, an intervention that has been shown to improve outcomes.

Researchers discuss their study of COPD patients who have experienced a first myocardial infarction and the impact of beta-blocker therapy on mortality.

University of Florida pharmacy researchers have isolated a compound from blue-green algae that may inhibit the progression of pulmonary disease.

The risk of depression in chronic obstructive pulmonary disease patients increases along with disease severity, according to the results of a new study.

Martin R. Stämpfli, PhD, explains the development of COPD in his lecture at the seminar "COPD-Bridging the Gap between Science and Clinical Care."

A recent study found that mild cognitive impairment was more likely in patients who had COPD, especially in those who had COPD for longer than 5 years.

These 7 points can help guide patient counseling sessions on COPD.

Patients who develop hyponatremia after cardiac surgery are more likely to spend longer in the hospital and are at increased risk for complications and death.

A new study finds that increased access to MTM services for Medicare Part D beneficiaries with chronic conditions could increase medication adherence, reduce costs, and improve outcomes.

Non-cardioselective beta-blockers appear to pose the greatest risk to patients with asthma or COPD.

A recently released review finds copious evidence that higher rates of medication adherence lead to improved health outcomes and reduced overall health care costs.

COPD patients who took azithromycin daily for a year were re-hospitalized at significantly lower rates than those who took placebo.

A review of current treatment recommendations for chronic obstructive pulmonary disease with a focus on currently available medication devices.